Clinical Trials Logo

Infantile Hemangioma clinical trials

View clinical trials related to Infantile Hemangioma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05479123 Recruiting - Clinical trials for Infantile Hemangioma

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

Start date: June 23, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the baseline sleep pattern disruption for patients starting oral propranolol at the standard BID dosing regimen compared to the control (timolol) group and to determine if there is a significant improvement in the sleep patterns in infants taking oral propranolol on the TID dosing regimen versus the control (timolol) group

NCT ID: NCT04288700 Recruiting - Clinical trials for Infantile Hemangioma

Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma

Start date: October 1, 2019
Phase: Phase 4
Study type: Interventional

Is to compare and evaluate the efficacy of oral captopril with oral propranolol, intralesional propranolol injection, and topical Timolol in the treatment of infantile hemangioma and their effect on vascular endothelial growth factor and CD 133.

NCT ID: NCT03842631 Recruiting - Clinical trials for Infantile Hemangioma

Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination

Start date: February 16, 2019
Phase:
Study type: Observational

The purpose of this study is to assess the safety and efficacy of Timolol Maleate treatment for different depth of infantile hemangioma based on B-ultrasonography. Based on the depth of hemangioma, patients will be proactively allocated to two groups. And then, all patients in both groups will receive topical timolol treatment in the same protocol and dosage.

NCT ID: NCT03237637 Recruiting - Clinical trials for Infantile Hemangioma

Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas

Start date: March 24, 2017
Phase: Phase 3
Study type: Interventional

Through this study, the investigators shall compare the effectiveness of atenolol with propranolol in the treatment of IH. In addition, the investigators shall try to elucidate the mechanism of action of beta blockers by assessing their action on triggers such as hypoxia. The study design will be a parallel group comparative study wherein patients of IH will be randomized into two groups. One group will receive propranolol and the other atenolol for a maximum period of 9 months. The patients will then be followed up regularly for regression of the IH based on Physician global assessment, hemangioma activity score(HAS), serial photography and lesional ultrasonography. Any side effects encountered during the treatment period will also be noted. Also serial measurements of hypoxia inducible factor 1 alpha(HIF-1α) will be made to ascertain the mechanism of action of the drugs.

NCT ID: NCT03173352 Recruiting - Clinical trials for Infantile Hemangioma

A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China

IH
Start date: December 2015
Phase: N/A
Study type: Observational

Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, the investigators designed the study for the following purposes: 1, to aware the incidence of infantile hemangioma and understand the related risk factorsin China; 2, to understand the clinical characteristics of infantile hemangioma and the risk factors for complications; 3, to investigate the level of knowledge, treatment options in infant hemangioma in Chinese doctors; 3, to improve the awareness of infantile hemangioma in parents and provide more advice for pregnancy counseling and eugenics.